Abstract
BackgroundThe immunogenic nature of melanoma has been exploited for the development of adoptive transfer of ex-vivo expanded tumor infiltrating lymphocytes (TIL). This adoptive cell transfer therapy has overall response rates...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have